FDAnews Announces — Making Sense of IVD Regulation: IVDs, LDTs, RUOs, IUOs, ASRs, or GPRs — Are You Following the Right Rules? Webinar, Oct. 19, 2017
Falls Church, VA (PRWEB) September 28, 2017 -- Making Sense of IVD Regulation:
IVDs, LDTs, RUOs, IUOs, ASRs, or GPRs — Are You Following the Right Rules?
**An FDAnews Webinar**
Oct. 19, 2017 — 1:30 p.m. – 3:00 p.m. ET
http://www.fdanews.com/senseivdreg
IVD regulation is among the most confusing areas of FDA regulation.
The IVD rules are scattered throughout the CFRs, and the FDA has issued few guidances to clear things up. Because these products are interrelated, knowing which guidance applies often isn’t clear. Example: Important aspects of GPRs (general purpose reagents) are in the guidance referring to ASRs (Analyte-Specific Reagents). There is no GPR guidance document.
FDAnews has called on one of its most popular presenters, Dan O’Leary of Ombu Enterprises, to straighten things out.
Mr. O’Leary has combed the CFR for every sentence that affects IVDs, and reorganized them by topic for ease of understanding. All participants get their own copy of his fully annotated worksheet. This unique FREE bonus could be worth the registration fee by itself.
The reorganization sheet provides a new framework to understand this complex regulatory area. In just 90 minutes, attendees will:
• Learn technical definitions of IVDs, LDTs, RUOs, IUOs, ASRs, and GPRs
• Learn practical definitions of these terms
• Understand the distinction between “finished devices”, “investigational products”, and “research products”
• Learn the pre-market submission paths, if needed, for these devices
• Understand the labeling requirement for these devices
• Understand when laboratories must include specific information on their reports
• Understand restrictions on sale to specific parties
• And much more!
Devicemakers, IVD marketers and clinical labs all are vulnerable to running afoul of the FDA in this confusing area. Why risk a Form 483, a warning letter or even worse? Seize this moment to clear up regulatory confusion.
Meet the Presenter:
Dan O’Leary is President of Ombu Enterprises LLC, a company offering training and execution in Operational Excellence via a systems approach to operations management. Mr. O’Leary boasts more than 30 years’ experience in quality, operations, and program management in regulated industries including medical devices, clinical labs, aviation and defense. He is an ASQ-certified Biomedical Auditor, Quality Auditor, Quality Engineer, Reliability Engineer, and Six Sigma Black Belt; and is certified by APICS in Resource Management.
Who Will Benefit:
IVD regulation cuts across many FDA-regulated industries. This webinar is for the IVD and lab communities as well as others affected by this confusing area of FDA rulemaking:
• Quality Managers of IVD manufacturers
• Lab Directors who use ASRs
• Lab Directors who perform High Complexity Testing under the CLIA regulations
• Regulatory Managers of IVD manufacturers
• Sales Managers of IVD manufacturers
• Compliance Managers of IVD manufacturers
• Compliance Managers of High Complexity labs
Webinar Details:
Making Sense of IVD Regulation:
IVDs, LDTs, RUOs, IUOs, ASRs, or GPRs — Are You Following the Right Rules?
**An FDAnews Webinar**
Oct. 19, 2017 — 1:30 p.m. – 3:00 p.m. ET
http://www.fdanews.com/senseivdreg
Tuition:
$287 per site
Easy Ways to Register:
Online: http://www.fdanews.com/senseivdreg
By phone: 888-838-5578 or 703-538-7600
About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.
Michelle Butler, FDANEWS, http://www.fdanews.com, +1 (703) 538-7665, [email protected]
Share this article